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CORRESPONDENCE
Letters to the Editor
The ACCF/AHA Scientific
Statement on Syncope Needs Rethinking
On behalf of a multidisciplinary international consortium of more
than 60 physicians experienced in caring for patients with episodic
transient loss of consciousness, including syncope, we write as an
Ad Hoc Syncope Consortium to highlight a number of concerns
regarding the recently published American College of Cardiology
Foundation/American Heart Association (ACCF/AHA) Scien-
tific Statement on the Evaluation of Syncope (“Statement”) (1).
The Statement was intended to provide guidance for physicians.
However, in our opinion it does not sufficiently address a number of
long-standing clinical misconceptions regarding the evaluation of
individuals who have seemingly suffered a transient loss of conscious-
ness (TLOC) episode. We raise these issues here, not simply to
highlight certain differences of opinion with the Statement, but, more
importantly, to encourage physicians to take a broader perspective in
evaluation and treatment of TLOC patients than is offered by the
Statement, and to encourage professional societies to work in concert
to develop multidisciplinary clinical practice guidelines.
Space limitation permits our pointing out only a few of the more
important concerns that we have with the Statement. First, it is
crucial for readers of the Statement to be able to put “syncope”
within the larger context of the many conditions that can cause real
or apparent TLOC. The Statement fails to consider this key step.
The Statement would be improved if it clearly distinguished “syncope”
(i.e., TLOC due to transient inadequate cerebral perfusion) from the
broader problem of TLOC, and thereby clarify from the beginning
what is, and what is not, syncope. Thus, for example, it is important
that the clinician be advised both why and how to differentiate
syncope from nonsyncope conditions such as epilepsy, concussion, or
psychogenic pseudo-syncope. To be fair to the Statement’s authors,
failure to highlight these same key points (2) is commonly found in
other current prominent medical writings (3,4).
Second, the Statement states that the primary “purpose of the
(syncope) evaluation” is “to determine whether the patient is at
increased risk for death.” Certainly mortality risk assessment is an
important concern, and must be a consideration in the overall
evaluation of TLOC patients. However, a more comprehensive
perspective is needed; most syncope patients have disabling con-
ditions that require attention but are not life-threatening. These
patients may indeed feel better knowing that they are not at
high-risk of death; nevertheless, they still want and need their
symptoms addressed and recurrences prevented. A revised ACCF/
AHA Syncope Statement could emphasize a broad fundamental
goal for the TLOC/syncope evaluation, namely the importance of
establishing the diagnosis underlying the patient’s symptoms with
sufficient confidence to assess prognosis and recommend a sensible
and, it is hoped, effective treatment strategy.
Third, we are concerned that a large body of medical evidence
underlying recent evolution of thought regarding the optimal
approach to TLOC/syncope management was overlooked. At its
outset, the Statement offers “to summarize the data that direct the
evaluation of . . . syncope.” However, recent relevant literature is
not cited; consequently, the reader is not provided immediate
access to up-to-date sources. In this regard, though it is true that
many published trials focus on treatment, the evaluation and
treatment processes cannot be readily divorced. The treatment
trials provide readers crucial insight into the appropriate evaluation
process. Consequently, although we acknowledge that the State-
ment may have had constraints placed on it with respect to length,
it would have been a stronger document had it provided a more
comprehensive assessment of important recent literature. For
example, the European Society of Cardiology Syncope Guidelines
(5,6) and findings from a number of important published con-
trolled trials would be of value to readers. Additionally, among
missing references are the two major North American pacing trials
targeting syncope patients (VPS [Vasovagal Pacing Study]-1,
VPS-2), an important beta-blocker trial (POST [Prevention of
Syncope Trial]), the only North American trial assessing syncope
management units (SEEDS [Syncope Evaluation in Emergency
Department Study]), and more than half-a-dozen European trials
assessing various aspects of syncope evaluation (references provided
on request). Furthermore, among studies cited in the Statement, 3
implantable cardioverter-defibrillator (ICD) trials and one drug
trial did not focus primarily on a “syncope” population per se; only
a single non-ICD trial that did enroll syncope patients was
included.
As a group representing many of the medical disciplines
concerned with the evaluation and treatment of TLOC/syncope
patients (cardiovascular medicine, emergency medicine, geriatrics,
neuroscience, and pediatrics), the Ad Hoc Syncope Consortium
recommends, and would be pleased to participate in, a prompt and
careful review and revision of the current Syncope Statement.
Ultimately, our goal and that of the Syncope Statement’s author-
ship is undoubtedly the same: to provide clinicians with an
ACCF/AHA document that incorporates an up-to-date,
evidence-based, multidisciplinary viewpoint on TLOC/syncope
management.
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REPLY
The writing group of the “Scientific Statement on the Evaluation
of Syncope” takes this opportunity to respond to the critique of this
document (1) by Dr. Benditt and colleagues. The goal of this
Scientific Statement, as set forth by the sponsoring organizations,
was to provide a concise, practical approach to the initial evaluation
of the patient with syncope within strict length limitations (2). The
document approaches the evaluation of syncope as a clinician
would when a patient presents to the office or hospital with such an
event. The emphasis of this document is placed on the recognition
of life-threatening clinical syndromes.
The criticisms of Dr. Benditt and colleagues can be grouped
into three categories. First, the definition of syncope was inade-
quate. Second, the stated goal of preventing death is not adequate,
and the goal for the evaluation of syncope should also be to
establish a diagnosis and provide a prognosis. Third, the citations
were incomplete.
The definition of syncope as “a transient loss of consciousness”
fits into the category of a practical working definition. Although
there is no uniform consensus on the ideal definition, the defini-
tion often includes reference to the loss of consciousness due to
global cerebral hypoperfusion. Unfortunately, this definition can
be strictly applied only when the mechanism of syncope is firmly
established. The definition used in this document relates to the
clinical presentation, as commonly used and understood, and does
not require a specific mechanistic diagnosis. Academically, one
might prefer a more detailed or thorough definition. However, one
could also argue that any definition intended to be used universally
should be developed by international consensus among appropriate
medical societies. To date, this has not been achieved.
The specific etiology of syncope is identified in only about
one-half of the patients who undergo an evaluation for syncope.
Furthermore, many patients never have a recurrence after an
episode of syncope, and only occasionally is syncope disabling.
Ultimately, one can have many goals for a document of this type.
We chose the identification of the patient at risk of death as the
primary one.
Dr. Benditt and colleagues correctly state that many references
relevant to syncope were not cited. Owing to space considerations
and the document’s focus on the evaluation of syncope, many
excellent papers could not be referenced. We agree that the
“Guidelines on Management (Diagnosis and Treatment) of Syn-
cope” developed by the European Society of Cardiology are
particularly important documents, and we apologize for omitting
them (3,4).
The “Scientific Statement on the Evaluation of Syncope” was
reviewed and evaluated by 50 outside reviewers. The document
was reviewed and approved by the American Heart Association
(AHA), American College of Cardiology Foundation, Heart
Rhythm Society, and the American Autonomic Society. Criticisms
and comments offered by these reviewers and organizations were
responded to and incorporated into the final document. Although
there are inherent limitations to any such document, the writing
group believes that the “Scientific Statement on the Evaluation of
Syncope” achieves the goals set forth by the AHA for this
document, and it provides a concise and practical approach to the
initial evaluation of syncope.
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Examining the Concept
of Preserved Systolic Function
Sophisticated analyses and the size of the Acute Decompensated
Heart Failure National Registry (ADHERE) database strengthen
the characterization of heart failure with preserved systolic func-
tion (PSF) made by Yancy et al. (1). Unfortunately, PSF includes
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